Render Target: STATIC
Render Timestamp: 2024-12-27T11:41:13.195Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-09-30 01:56:54.232
Product last modified at: 2024-12-18T13:45:15.740Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

STEAP1 (D8B2V) Rabbit mAb #88677

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H R
    SENSITIVITY Endogenous
    MW (kDa) 30
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 
    • R-Rat 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    STEAP1 (D8B2V) Rabbit mAb recognizes endogenous levels of total STEAP1 protein. This antibody also recognizes overexpressed STEAP1B isoform 1 protein and may recognize endogenous STEAP1B isoform 1 protein.

    Species Reactivity:

    Human, Rat

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human STEAP1 protein.

    Background

    Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a transmembrane protein abundantly expressed in normal prostate epithelial cells (1). It is a metalloreductase that reduces Fe3+ to Fe2+ and Cu2+ to Cu1+ (2). STEAP1 is also reportedly overexpressed in multiple tumor types, and has been used as a cell surface biomarker for prostate cancer and Ewing's sarcoma (3-6). Peptides derived from STEAP1 protein have been shown to induce an antigen-specific cytotoxic T lymphocyte (CTL) response that can kill tumor cells expressing STEAP1 (7). These finding are the basis for research studies examining the efficacy of antibody-drug conjugates (ADCs) targeting STEAP1 (8,9).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.